Veerhealth Care Ltd (511523)
சுருக்கம்
The board meets on 14 Nov 2026 to consider the Q2 FY27 results.
நிகழ்வுகள்
- அடுத்த முடிவுகள்
- 14 நவ. 2026 (Q2 FY27)
- சமீபத்திய முடிவுகள்
- Q1 FY27, தாக்கல் செய்யப்பட்டது 14 ஆக. 2026
- இயக்குநர் குழுக் கூட்ட அறிவிப்பு
- 5 ஆக. 2026
பங்குச் சந்தைத் தரவு. ஒவ்வொரு எண்ணும் அதன் சொந்தப் பக்கம் காட்டும் வடிவத்திலேயே; தேதிகள் தரவின் தேதிகள். தகவலுக்கு மட்டுமே, முதலீட்டு ஆலோசனை அல்ல.
📈 பங்கு விலை & நிகழ்வுகள்
Q2 FY27 முடிவுகள்
📅 அடுத்த நிதி முடிவுகள்: 14 நவ. 2026 (இயக்குநர் குழுக் கூட்டம்)Veerhealth Care Ltd-இன் இயக்குநர் குழுக் கூட்டம் 14 நவ. 2026 அன்று நடைபெறுகிறது; அதில் அதன் Q2 FY27 முடிவுகள் பரிசீலிக்கப்படும் (ஜூலை-செப்டம்பர் 2026).
In its latest reported quarter, Q1 FY27, Veerhealth Care's revenue was ₹24.9 Cr (+455.1% year on year, +48.7% on the previous quarter), and net profit ₹1.2 Cr (+411.1% year on year); the operating margin was 7.7%.
| Q1 FY27 (₹ கோடி) | மதிப்பு | YoY Q1 FY26-உடன் | QoQ |
|---|---|---|---|
| வருவாய் | ₹24.9 | +455.1% | +48.7% |
| செயல்பாட்டு லாபம் | ₹1.9 | நஷ்டத்திலிருந்து | +161.3% |
| நிகர லாபம் | ₹1.2 | +411.1% | நஷ்டத்திலிருந்து |
| EPS (₹) | 0.61 | +408.3% | நஷ்டத்திலிருந்து |
| செயல்பாட்டு லாப வரம்பு | 7.7% | — | — |
📢 சமீபத்திய கார்ப்பரேட் அறிவிப்புகள்
Veerhealth Care released the transcript of its October 24, 2026 investor meeting detailing aggressive operational growth. The management stated it aims to close FY27 with approximately ₹100 crore in turnover and ₹5-6 crore in PAT, compared to TTM revenue of ₹53 crore. In Q1 FY27, revenue reached ₹25 crore with ₹1.25 crore PAT, driven 70% by contract manufacturing, 20% by exports, and 10% by own brands. The company is operating at 65-70% capacity at its Vapi facility, which will rise toward 90% post-expansion.
- Targets ₹100 crore turnover and ₹5 to 6 crore PAT for FY 26-27 (target revenue is ~1.89x TTM revenue)
- Reported Q1 revenue of ₹25 crore and profit of ₹1.25 crore
- Current Vapi manufacturing capacity utilization stands at 65% to 70%, expected to reach ~90% post-expansion
- Revenue mix for Q1 FY27 comprised 70% contract manufacturing, 20% exports, and 10% own brand
- Acquired 30,000 sq ft adjacent land in Oct 2024, expanding production footprint from ~60,000 to ~90,000 sq ft
Veerhealth Care Ltd submitted the outcome of an analyst and institutional investor meeting held virtually on October 24, 2026. A total of 22 individual and institutional attendees, including representatives from S&P Global, participated in the 45-minute group session. The company confirmed that discussions were based strictly on generally available information and no unpublished price-sensitive information (UPSI) was shared. This is a routine post-meeting disclosure per Regulation 30 requirements without any quantitative or operational announcements.
- Meeting conducted on October 24, 2026, from 3:00 PM to 3:45 PM IST
- List of participants comprises 22 attendees including institutional and individual analysts
- Discussions were conducted in virtual mode via Microsoft Teams
- Company confirmed no Unpublished Price Sensitive Information (UPSI) was shared
Veerhealth Care Ltd has secured an order worth Rs 454.68 Lakhs (approx. Rs 4.55 crore) for the supply of face care products from an unnamed leading domestic FMCG company. The order comes with a short execution timeline of 45 days. Relative to the company's TTM revenue of Rs 53 crore, this single order represents approximately 8.6%, offering immediate quarterly revenue visibility. The contract is non-related party and awarded on an arm's length basis.
- Received skincare order worth Rs 454.68 Lakhs from a domestic FMCG firm
- Order execution period is within 45 days
- Scope involves supply of face care products
- Non-related party transaction with no promoter interest
Veerhealth Care has announced that its 34th Annual General Meeting (AGM) will be conducted via Video Conferencing on Wednesday, September 23, 2026, at 16:00 IST. The company dispatched communications containing the web-link to the FY 2025-2026 Annual Report to shareholders without registered email addresses as of the August 21, 2026 cut-off date. The letter also reminds physical shareholders to update mandatory KYC and banking details per SEBI regulations.
- 34th Annual General Meeting scheduled for September 23, 2026, at 16:00 IST via VC/OAVM
- Cut-off date for unregistered shareholder dispatch set as August 21, 2026
- Annual Report FY25-26 made available online at company website
- Physical security holders urged to complete mandatory KYC updates under SEBI circular dated May 7, 2024
Veerhealth Care reported a 388.13% YoY surge in Q1FY27 total revenue to Rs 25.09 crore, with net profit rising 412.50% YoY to Rs 1.23 crore. The company highlighted major order wins in FY27, including Rs 32.93 crore from a New York-based firm and Rs 18.24 crore from a domestic FMCG firm. Management issued strong guidance targeting Rs 105 crore in total income with Rs 5-6 crore PAT for FY27, and Rs 156 crore total income for FY28. Growth is supported by a newly commenced manufacturing facility and USFDA plant clearance for OTC exports.
- Q1FY27 total revenue rose 388.13% YoY to Rs 25.09 crore, with PAT up 412.50% YoY to Rs 1.23 crore.
- EBITDA increased 233.87% YoY to Rs 2.07 crore, though EBITDA margin contracted 381 bps YoY to 8.25%.
- Secured sizeable order wins in FY27, including Rs 32.93 crore from New York and Rs 18.24 crore from an Indian FMCG player.
- Management guided FY27 revenue of Rs 105 crore (PAT Rs 5-6 crore) and FY28 revenue of Rs 156 crore (PAT Rs 9-10 crore).
Veerhealth Care reported a massive surge in Q1 FY27 (June 2026) revenue to ₹24.93 Cr, a 455% increase compared to ₹4.49 Cr in the same quarter last year. The company turned profitable with a net profit of ₹1.23 Cr, recovering from a loss of ₹0.35 Cr in the preceding March 2026 quarter. Additionally, the company has received ₹4.87 Cr as part payment for 1 crore warrants issued at ₹20.25 each. The board also appointed Ruchi Shah, daughter of the Chairperson, as the new Company Secretary following the resignation of Ashita Chittora.
- Revenue from operations grew 455.7% YoY to ₹24.93 Cr in Q1 FY27.
- Net profit stood at ₹1.23 Cr for the quarter, compared to ₹0.24 Cr in Q1 FY26.
- Received ₹4.87 Cr towards 1,00,00,000 warrants convertible at ₹20.25 per share.
- Basic EPS improved to ₹0.61 from ₹0.12 YoY and a negative ₹0.18 in the previous quarter.
- New CS Ruchi Shah appointed, who is the daughter of Chairperson Mr. Yogesh Shah.
Veerhealth Care reported a massive surge in Q1 FY27 revenue to ₹24.93 cr, a 455% increase from ₹4.49 cr in the same quarter last year. Net profit rose to ₹1.23 cr compared to ₹0.24 cr YoY, marking a sharp recovery from the ₹0.35 cr loss in the preceding March 2026 quarter. The company also confirmed receiving ₹4.87 cr as part payment for a ₹20.25 cr warrant issue. Additionally, the Board appointed Ruchi Shah, daughter of the Chairperson, as the new Company Secretary following the resignation of the incumbent.
- Revenue from operations grew 455% YoY to ₹24.93 cr from ₹4.49 cr.
- Net profit increased to ₹1.23 cr from ₹0.24 cr in the year-ago period.
- Quarterly EPS improved to ₹0.61 from ₹0.12 in June 2025.
- Received ₹4.87 cr towards the issuance of 1,00,00,000 warrants priced at ₹20.25 each.
- Total expenses rose to ₹23.61 cr, largely driven by stock-in-trade purchases of ₹25.51 cr.
Veerhealth Care has secured a repeat monthly order worth ₹5.27 Crores from a prominent 125-year-old Indian FMCG group for face care products. This single order represents approximately 16.5% of the company's TTM revenue and is scheduled for execution within 45 days. Additionally, the company has entered the Sudan market with a ₹15.74 lakh sample order for Gripe Water. Management has issued aggressive guidance, targeting ₹105 Crores in revenue for FY27, which would be a 223% increase over FY26 revenue of ₹32.48 Crores.
- Received a repeat monthly order worth ₹5.27 Crores for face care products from a major FMCG client.
- Order execution timeline is set for within 45 days.
- Management projects FY27 total income of ₹105 Crores with a PAT of ₹5-6 Crores.
- Secured first export sample order from Sudan worth ₹15.74 lakhs.
- Company is in advanced talks with a large Indo-Canadian hotel amenities supplier.
Veerhealth Care Ltd has scheduled a board meeting for August 13, 2026, to consider and approve the unaudited financial results for the quarter ended June 30, 2026. Additionally, the board will approve the Director's Report for the financial year ended March 31, 2026, and finalize the notice for the 34th Annual General Meeting. This follows a fiscal year (FY26) where revenue grew 95% to ₹32.48 cr, though the company reported a net loss of ₹0.35 cr in the most recent March 2026 quarter. The trading window for insiders will reopen on August 16, 2026.
- Board meeting scheduled for August 13, 2026, to approve Q1 FY27 results.
- Trading window for securities to reopen on August 16, 2026.
- Board to approve the draft notice for the 34th Annual General Meeting.
- Meeting will also finalize the Director's Report for the financial year ending March 31, 2026.
Veerhealth Care has secured a domestic order worth ₹526.84 Lakhs (₹5.27 Cr) for the supply of face care products to a major Indian FMCG company. This single order is highly material, representing approximately 16.5% of the company's total FY26 revenue of ₹32.48 Cr. The contract requires rapid execution within a 45-day window, which is expected to significantly impact the immediate quarterly turnover. While the client's identity is withheld due to confidentiality, the scale of the win is substantial for a micro-cap company with an ₹84 Cr market valuation.
- Received a domestic order valued at ₹526.84 Lakhs for skincare products.
- Order execution timeline is strictly set at 45 days.
- Order value represents ~16.5% of the company's TTM revenue of ₹32 Cr.
- Contract awarded by one of India's largest FMCG companies (name withheld).
- Focus of the order is specifically on the supply of Face Care Products.
Veerhealth Care has secured its first export order from Sudan for the supply of Gripe Water, valued at Rs. 15.74 lakhs. While the order size is small, representing approximately 0.49% of the company's TTM revenue of Rs. 32 Cr, it marks a strategic entry into the African pediatric care market. The contract is scheduled for execution within a 45-day timeline. This development follows a period of high stock price volatility, with the company reporting a net loss of Rs. 0.35 Cr in the most recent quarter (Mar 2026).
- Secured export order valued at Rs. 15,73,992 for Gripe Water supply
- Execution timeline mandated within 45 days from the order date
- Marks the company's first strategic entry into the Sudan market
- Order value represents ~0.49% of TTM revenue (Rs. 32 Cr)
- Targeting expansion in the pediatric and wellness care segment in Africa
Veerhealth Care has secured a sample order worth Rs 76.40 lakhs from a prominent 125-year-old Indian FMCG group for skincare products. While the order is small at approximately 2.4% of TTM revenue, it is strategically significant as it involves a new MRP structure for brand promotion and market expansion. The company has also issued aggressive forward guidance, targeting a revenue of Rs 105 crore in FY27, which is more than 3x its current TTM revenue of Rs 32 crore. Execution of this specific order is expected within 45 days.
- Received a new sample order worth Rs 76.40 lakhs for skincare products from a leading FMCG company.
- Order execution timeline set for 45 days from the date of receipt.
- Company projected FY27 total income of Rs 105 crore with a minimum PAT of Rs 5-6 crore.
- Company projected FY28 total income of Rs 156 crore with a minimum PAT of Rs 9-10 crore.
- Reported book value per share for FY26 at Rs 11.46, expected to increase with preferential warrant funds.
Veerhealth Care has received a repeat order worth ₹1.11 crores for hair and oral care products from a major Indian pharmacy and hospital network, with execution slated within 45 days. The company has issued aggressive financial guidance, targeting a total income of ~₹105 crores in FY27 and ~₹156 crores in FY28. To fund this growth, the company is raising capital through the allotment of 1,00,00,000 convertible warrants at ₹20.25 each. Promoters are demonstrating confidence by subscribing to 45.37% of the total warrant issue.
- Received a repeat order worth ₹1.11 crores for Hair Care and Oral Care products from a leading healthcare network.
- Projected Total Income of ~₹105 crores for FY 2026-27 with a minimum PAT of ~₹5-6 crores.
- Approved allotment of 1,00,00,000 fully convertible warrants at an issue price of ₹20.25 per warrant.
- Promoters to contribute 45,37,000 warrants out of the total 1 crore warrants issued.
- Order execution is committed within a short timeframe of 45 days.
நிறுவனச் சுயவிவரம்
நிதிச் செயல்திறன்
இந்த நிறுவனத்துக்கான நிதிப் பகுப்பாய்வுத் தரவு இன்னும் கிடைக்கவில்லை.
செயல்பாட்டு உந்துசக்திகள்
இந்த நிறுவனத்திற்கான செயல்பாட்டுப் பகுப்பாய்வுத் தரவு இன்னும் கிடைக்கவில்லை.
வியூக வளர்ச்சி
இந்த நிறுவனத்துக்கான வியூக வளர்ச்சிப் பகுப்பாய்வு இன்னும் கிடைக்கவில்லை.
வெளிப்புறக் காரணிகள்
இந்த நிறுவனத்துக்கு வெளிப்புறக் காரணிகளின் பகுப்பாய்வு இன்னும் கிடைக்கவில்லை.
ஒழுங்குமுறை & நிர்வாகம்
இந்த நிறுவனத்திற்கான ஒழுங்குமுறைப் பகுப்பாய்வு இன்னும் கிடைக்கவில்லை.
அபாயப் பகுப்பாய்வு
இந்நிறுவனத்துக்கான அபாய பகுப்பாய்வு இன்னும் கிடைக்கவில்லை.
